$200
per visit
24 months
Duration
24
Total Visits
61
Spots Remaining
About This Study
This study investigates a combination immunotherapy approach for patients with advanced melanoma who have not responded to standard treatments. The therapy targets multiple immune checkpoints to enhance the body's natural ability to fight cancer.
Study Objectives
To determine the overall response rate and progression-free survival of the combination therapy.
Eligibility Requirements
Inclusion Criteria
- Adults 18 years and older
- Confirmed diagnosis of Stage III or IV melanoma
- At least one prior line of therapy
- ECOG performance status 0-1
- Adequate organ function
Exclusion Criteria
- Active autoimmune disease
- Prior organ transplant
- Active brain metastases
- Current immunosuppressive therapy
Frequently Asked Questions
Study Location
MD Anderson Cancer Center
Houston, TX 77030
Map View
Research Team
Dr. Michael Rodriguez
MD Anderson Cancer Center
Melanoma Research Team
Study Timeline
Start DateJanuary 15, 2024
End DateJanuary 15, 2026
Enrollment89 / 150